stickey-banner-728x90
Cytiva-Banner-800x220
Pharma Focus America
TFS Chemicals - Aspire

LATEST NEWSRead more...

19

Apr 2024

GV20 Therapeutics Teams Up for Clinical Trial to Test GV20-0251, an Innovative IGSF8 Antagonist Antibody, Alongside KEYTRUDA® (pembrolizumab)

GV Therapeutics a prominent biotechnology company at the forefront of integrating AI genomics and disease biology has made a significant announcement Theyve partnered with Merck

17

Apr 2024

Medincell Collaborates with AbbVie to Develop Next-generation Long-acting Injectable Therapies

Medincell has announced a collaboration with AbbVie to jointly develop and commercialize up to six therapeutic products across various therapeutic areas and indications The partnership aims to utilize

17

Apr 2024

NMDP BioTherapies Unveils Enhanced Cellular Materials for Allogeneic Cell Therapy Advancement

NMDP BioTherapies formerly Be The Match BioTherapies has recently announced significant upgrades to its cellular starting material offerings including the addition of a Drug Master File

16

Apr 2024

Spinogenix Receives FDA Approval for Phase 2a Clinical Trial of SPG601 in Fragile X Syndrome

Spinogenix Inc a company specializing in developing innovative therapies aimed at restoring synaptic function to enhance the lives of patients worldwide has received clearance from the US Food and Drug

15

Apr 2024

AviadoBio Initiates ASPIRE-FTD Clinical Trial Assessing AVB-101 for Frontotemporal Dementia

AviadoBio a pioneering gene therapy company dedicated to developing transformative medicines for neurodegenerative disorders has recently initiated the Phase ASPIREFTD trial This trial

press releasesRead more...

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

Genentech a member of the Roche Group announced today that the US Food and Drug Administration has approved Alecensa for adjuvant treatment following

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

Psyence Biomedical Ltd today announced that details of its upcoming Phase IIb clinical trial of naturederived psilocybin in patients diagnosed with Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor

Ventus Therapeutics a clinicalstage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform ReSOLVE

CancerVax Announces Promising New Drug to Treat a Deadly Children’s Cancer

CancerVax Inc the developer of breakthrough cancer drugs that will use the bodys immune system to fight cancer today announced that its UCLA research team has created a promising new drug candidate for treating recurrent

17 - 19

Apr 2024

CPHI Japan

Tokyo, Japan

18 - 19

Apr 2024

22 - 24

Apr 2024

23 - 25

Apr 2024

24 - 26

Apr 2024

Lab Indonesia 2024

Jakarta, Indonesia

Testing The WorldCelebrating 70 Years of Nalgene
Sartorius - 6th Edition Live-Cell Imaging
patheon - Mastering API production at every scale
Future Labs Live USA 2024
patheon - Revolutionizing Pharma
Cytiva-square-Banner-300x600

TOP ARTICLES

  • 1

    Advanced Hot Melt Extrusion: Pioneering Techniques in Pharmaceutical Formulation

    Kate Williamson

    Kate, Editorial Team at Pharma Focus America, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.

  • 2

    Revolutionizing Drug Discovery: The Rise of AI-Powered Platforms

    Kate Williamson

    Kate, Editorial Team at Pharma Focus America, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.

  • 3

    Latest Innovations Driving Progress in CNS Drug Development

    Kate Williamson

    Kate, Editorial Team at Pharma Focus America, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.

  • 4

    Revolutionizing Pharmaceuticals: The Dynamic Evolution of Mass Spectrometry

    Kate Williamson

    Kate, Editorial Team at Pharma Focus America, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.

  • 5

    Vectorizing Hope: The Art and Science of Gene Therapy Vector Manufacturing

    Kate Williamson

    Kate, Editorial Team at Pharma Focus America, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.

KNOWLEDGE BANK

EDITORIAL SECTION

  • Information Technology

    How AI is Transforming the Pharma Industry

    The global pharmaceutical industry is currently facing many wide ranging challenges including an aging population increased life expectancy a rise in chronic conditions reduced funding for treatments reduced numbers of clinical staff the ever increasing cost of drug development and raw materials and supply chain issues